Department of Bacteriology I, National Institute of Infectious Diseases, Tokyo, Japan.
Division of Biophysics, Kobe University Graduate School of Health Sciences, Kobe, Japan.
J Antimicrob Chemother. 2019 Jul 1;74(7):1812-1819. doi: 10.1093/jac/dkz129.
Ceftriaxone resistance in Neisseria gonorrhoeae is a major public health concern globally because a high-dose (1 g) injection of ceftriaxone is the only remaining option for empirical monotherapy of gonorrhoea. The ceftriaxone-resistant gonococcal strain FC428, cultured in Osaka in 2015, is suspected to have spread nationally and internationally. We describe the complete finished genomes of FC428 and two closely related isolates from Osaka in 2015, and examine the genomic epidemiology of these isolates plus three ceftriaxone-resistant gonococcal isolates from Osaka and Hyogo in 2016-17 and four ceftriaxone-resistant gonococcal isolates cultured in 2017 in Australia, Canada and Denmark.
During 2015-17, we identified six ceftriaxone-resistant gonococcal isolates through our surveillance systems in Kyoto, Osaka and Hyogo. Antimicrobial susceptibility testing (six antimicrobials) was performed using Etest. Complete whole-genome sequences of the first three isolates (FC428, FC460 and FC498) from 2015 were obtained using PacBio RS II and Illumina MiSeq sequencing. The three complete genome sequences and draft genome sequences of the three additional Japanese (sequenced with Illumina MiSeq) and four international ceftriaxone-resistant isolates were compared.
Detailed genomic analysis suggested that the Japanese isolates (FC428, FC460, FC498, KU16054, KM383 and KU17039) and the four international MLST ST1903 isolates from Australia, Canada and Denmark formed four linked subclades.
Using detailed genomic analysis, we describe the clonal expansion of the ceftriaxone-resistant N. gonorrhoeae strain FC428, initially identified in 2015 in Japan, and closely related isolates. FC428 and its close relatives show some genomic diversity, suggesting multiple genetic subclades are already spreading internationally.
淋病奈瑟菌对头孢曲松的耐药性是一个全球性的主要公共卫生问题,因为高剂量(1 克)头孢曲松注射是淋病经验性单药治疗的唯一选择。2015 年在大阪培养的头孢曲松耐药淋病菌株 FC428 疑似已在国内外传播。我们描述了 2015 年 FC428 及其在大阪的两个密切相关分离株的完整完成基因组,并研究了这些分离株以及 2016-17 年在大阪和兵库的三个头孢曲松耐药淋病分离株和 2017 年在澳大利亚、加拿大和丹麦培养的四个头孢曲松耐药淋病分离株的基因组流行病学。
在 2015-17 年期间,我们通过在京都、大阪和兵库的监测系统发现了六株头孢曲松耐药淋病分离株。使用 Etest 进行了药敏试验(六种抗生素)。获得了 2015 年的前三个分离株(FC428、FC460 和 FC498)的全基因组序列,使用 PacBio RS II 和 Illumina MiSeq 测序。比较了三个日本分离株(用 Illumina MiSeq 测序)和四个国际头孢曲松耐药分离株的三个完整基因组序列和三个草案基因组序列。
详细的基因组分析表明,日本分离株(FC428、FC460、FC498、KU16054、KM383 和 KU17039)和来自澳大利亚、加拿大和丹麦的四个国际 MLST ST1903 分离株形成了四个连锁亚群。
通过详细的基因组分析,我们描述了 2015 年在日本首次发现的头孢曲松耐药淋病奈瑟菌菌株 FC428 及其密切相关分离株的克隆扩张。FC428 及其近亲显示出一些基因组多样性,表明多个遗传亚群已经在国际上传播。